Hunan Dajiaweikang Pharmaceutical IndustryLtd Balance Sheet Health
Financial Health criteria checks 2/6
Hunan Dajiaweikang Pharmaceutical IndustryLtd has a total shareholder equity of CN¥1.8B and total debt of CN¥3.1B, which brings its debt-to-equity ratio to 170.4%. Its total assets and total liabilities are CN¥6.3B and CN¥4.4B respectively. Hunan Dajiaweikang Pharmaceutical IndustryLtd's EBIT is CN¥176.5M making its interest coverage ratio 1.4. It has cash and short-term investments of CN¥402.5M.
Key information
170.4%
Debt to equity ratio
CN¥3.14b
Debt
| Interest coverage ratio | 1.4x |
| Cash | CN¥402.45m |
| Equity | CN¥1.84b |
| Total liabilities | CN¥4.43b |
| Total assets | CN¥6.28b |
Recent financial health updates
No updates
Recent updates
There's Reason For Concern Over Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd's (SZSE:301126) Massive 41% Price Jump
Oct 08
Optimistic Investors Push Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) Shares Up 30% But Growth Is Lacking
May 09Market Might Still Lack Some Conviction On Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) Even After 31% Share Price Boost
Mar 08Financial Position Analysis
Short Term Liabilities: 301126's short term assets (CN¥3.8B) exceed its short term liabilities (CN¥3.0B).
Long Term Liabilities: 301126's short term assets (CN¥3.8B) exceed its long term liabilities (CN¥1.4B).
Debt to Equity History and Analysis
Debt Level: 301126's net debt to equity ratio (148.5%) is considered high.
Reducing Debt: 301126's debt to equity ratio has increased from 48.3% to 170.4% over the past 5 years.
Debt Coverage: 301126's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 301126's interest payments on its debt are not well covered by EBIT (1.4x coverage).